BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.

BerGenBio is developing innovative drugs for aggressive diseases including cancer and severe respiratory infections.

BerGenBio was founded in 2007 by David Micklem and James Lorens. The company is headquartered in Bergen, Hordaland, Norway.

 

BerGenBio's lead compound, bemcentinib, is a potentially first-in-class, oral, highly selective inhibitor of the receptor tyrosine kinase AXL, which is expressed and activated in response to oxidative stress, inflammation, hypoxia, and drug treatment, resulting in a number of deleterious effects in cancer and severe respiratory infections.

 

Bemcentinib selectively inhibits AXL activation to prevent the progression of serious diseases through the modulation of resistance mechanisms and the adaptive immune system.

 

Bemcentinib is currently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. Its novel mechanisms of action and primary accumulation in the lungs uniquely position it to address these severe lung diseases. 

 

BerGenBio is backed by Meteva AS, Sarsia Seed Management, Investinor, Birk Venture, and others. The company raised NOK100M in a Post-IPO debt financing on Oct 25, 2022. This brings BerGenBio's total funding to $157M to date.

 

 

  • Year founded: 2007
  • Funding Info: $157M over 6 Rounds (Last Funding Type: Post-IPO Debt)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Bergen
  • State: Vestland
  • Country: Norway
Related businesses